Business · 12/12/2025
FDA Clears BACTROBAN (Mupirocin) Nasal Ointment for Approval
The FDA has determined that BACTROBAN (mupirocin) nasal ointment, 2%, was not withdrawn from sale due to safety or effectiveness concerns, paving the way for potential approval of generic versions.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →